DE69522188T2 - Verwendung von Substanz P Antagonist im pharmazeutischer Zusammensetzung - Google Patents

Verwendung von Substanz P Antagonist im pharmazeutischer Zusammensetzung

Info

Publication number
DE69522188T2
DE69522188T2 DE69522188T DE69522188T DE69522188T2 DE 69522188 T2 DE69522188 T2 DE 69522188T2 DE 69522188 T DE69522188 T DE 69522188T DE 69522188 T DE69522188 T DE 69522188T DE 69522188 T2 DE69522188 T2 DE 69522188T2
Authority
DE
Germany
Prior art keywords
antagonist
substance
pharmaceutical composition
pharmaceutical
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Revoked
Application number
DE69522188T
Other languages
English (en)
Other versions
DE69522188D1 (de
Inventor
Lacharriere Olivier De
Lionel Breton
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LOreal SA
Original Assignee
LOreal SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9469929&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69522188(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by LOreal SA filed Critical LOreal SA
Publication of DE69522188D1 publication Critical patent/DE69522188D1/de
Application granted granted Critical
Publication of DE69522188T2 publication Critical patent/DE69522188T2/de
Anticipated expiration legal-status Critical
Revoked legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/41—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/046—Tachykinins, e.g. eledoisins, substance P; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/74—Biological properties of particular ingredients
    • A61K2800/75—Anti-irritant
DE69522188T 1994-12-19 1995-11-15 Verwendung von Substanz P Antagonist im pharmazeutischer Zusammensetzung Revoked DE69522188T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9415251A FR2728265A1 (fr) 1994-12-19 1994-12-19 Utilisation d'un antagoniste de substance p dans une composition pharmaceutique

Publications (2)

Publication Number Publication Date
DE69522188D1 DE69522188D1 (de) 2001-09-20
DE69522188T2 true DE69522188T2 (de) 2001-11-29

Family

ID=9469929

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69522188T Revoked DE69522188T2 (de) 1994-12-19 1995-11-15 Verwendung von Substanz P Antagonist im pharmazeutischer Zusammensetzung

Country Status (14)

Country Link
US (2) US5679360A (de)
EP (1) EP0717997B1 (de)
JP (1) JPH08208506A (de)
AR (1) AR000509A1 (de)
AT (1) ATE204177T1 (de)
BR (1) BR9505382A (de)
CA (1) CA2165520C (de)
DE (1) DE69522188T2 (de)
ES (1) ES2160680T3 (de)
FR (1) FR2728265A1 (de)
HU (1) HU218921B (de)
MX (1) MX9505181A (de)
PL (1) PL311916A1 (de)
RU (1) RU2146519C1 (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2719474B1 (fr) * 1994-05-05 1996-05-31 Oreal Utilisation d'un antagoniste de substance P dans une composition cosmétique et composition obtenue.
US6203803B1 (en) * 1994-12-14 2001-03-20 Societe L'oreal S.A. Use of a substance P antagonist in a cosmetic composition, and the composition thus obtained
FR2732221B1 (fr) * 1995-03-28 1997-04-25 Oreal Utilisation d'un antagoniste de cgrp pour traiter les rougeurs cutanees d'origine neurogene et composition obtenue
FR2738742B1 (fr) * 1995-09-19 1997-11-14 Oreal Utilisation d'au moins une eau thermale de vichy en tant qu'antagoniste de substance p
FR2742054B1 (fr) * 1995-12-06 1998-01-09 Synthelabo Compositions pharmaceutiques contenant un agent anti-inflammatoire et des ceramides vegetales
US7135191B2 (en) * 1997-09-04 2006-11-14 Zsolt Istvan Hertelendy Urogenital or anorectal transmucosal vaccine delivery system
FR2768624B1 (fr) * 1997-09-25 1999-11-12 Oreal Utilisation d'un inhibiteur d'acides amines excitateurs dans une composition cosmetique ou dermatologique pour peaux sensibles et composition obtenue
US6214318B1 (en) 1997-10-02 2001-04-10 Oms Holdings Llc Aerosol ointment compositions for topical use
DE19902529A1 (de) * 1999-01-22 2000-08-03 Goldwell Gmbh Haarbehandlungsmittel
DE19902530C1 (de) * 1999-01-22 2000-05-25 Goldwell Gmbh Verwendung eines Mittels zum Behandeln von menschlichen Haaren
EP1295599A1 (de) * 2001-09-21 2003-03-26 Boehringer Ingelheim International GmbH Verfahren zur Behandlung oder Verhütung von atopischer Dermatitis
EP2075252B1 (de) 2006-10-16 2015-07-29 Lion Corporation Nk1-rezeptorantagonistenzusammensetzung
WO2011116277A1 (en) * 2010-03-19 2011-09-22 Oxygen Biotherapeutics, Inc. Perfluorocarbon eye cream formulations
RU2443439C2 (ru) * 2010-05-05 2012-02-27 Федеральное государственное учреждение "Уральский научно-исследовательский институт дерматовенерологии и иммунопатологии Федерального агентства по высокотехнологичной медицинской помощи" (ФГУ "УрНИИДВиИ Росмедтехнологий") Способ лечения красного плоского лишая
WO2012044963A2 (en) * 2010-10-01 2012-04-05 Oxygen Biotherapeutics, Inc. Perfluorocarbons for use in treating pruritus
WO2014057003A1 (en) 2012-10-11 2014-04-17 Nerre Therapeutics Limited Novel uses
US8906951B1 (en) 2013-06-24 2014-12-09 Tigercat Pharma, Inc. Use of NK-1 receptor antagonists in pruritus
US9198898B2 (en) 2013-06-24 2015-12-01 Tigercat Pharma, Inc. Use of NK-1 receptor antagonists in pruritus
US20170290774A1 (en) * 2014-07-24 2017-10-12 Plus Vitech, S.L. Neurokinin-1 receptor antagonist composition for treatment of diseases and conditions of the respiratory tract

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3888976A (en) * 1972-09-21 1975-06-10 William P Mlkvy Zinc and strontium ion containing effervescent mouthwash tablet
US3772431A (en) * 1972-09-21 1973-11-13 W Mlkvy Effervescent mouthwash tablet
US4477439A (en) * 1981-04-13 1984-10-16 Walter J. Monacelli Treatment of irritated and excoriated areas around the stoma of ostomy patients
EP0090798A1 (de) * 1981-10-09 1983-10-12 Ferring AB Arzneimittel auf der basis eines antagonisten der p-substanz
US4837026A (en) * 1985-10-03 1989-06-06 Rajakhyaksha Vithal J Transdermal and systemic preparation and method
DE3584837D1 (de) * 1985-10-08 1992-01-16 Psori Med Ag Salzmischung zur behandlung der schuppenflechte (psoriasis) und anderer hautkrankheiten.
US4986981A (en) * 1986-07-07 1991-01-22 Den Mat Corporation Toothpaste having low abrasion
US5091171B2 (en) * 1986-12-23 1997-07-15 Tristrata Inc Amphoteric compositions and polymeric forms of alpha hydroxyacids and their therapeutic use
SE8701372L (sv) * 1987-04-02 1988-10-03 Boliden Ab Foerfarande och medel foer konservering av hoe
DE3929411A1 (de) * 1988-09-22 1990-03-29 Siegfried Natterer Pharmazeutische zubereitung sowie verfahren zu ihrer herstellung
CA2014201A1 (en) * 1989-04-26 1990-10-26 Albemarle Corporation Solid non-hygroscopic trialkylamine oxides
US5202130A (en) * 1989-08-31 1993-04-13 The Johns Hopkins University Suppression of eczematous dermatitis by calcium transport inhibition
WO1991012266A1 (en) * 1990-02-15 1991-08-22 Fujisawa Pharmaceutical Co., Ltd. Peptide compound
CA2110513A1 (en) * 1991-07-05 1993-01-21 Christopher J. Swain Aromatic compounds, pharmaceutical compositions containing them and their use in therapy
ATE133658T1 (de) * 1991-07-10 1996-02-15 Merck Sharp & Dohme Aromatische verbindungen diese enthaltende pharmazeutische zusammensetzungen und ihre therapeutische verwendung
US5527808A (en) * 1991-09-26 1996-06-18 Pfizer Inc. Fused tricyclic nitrogen containing heterocycles
GB9201179D0 (en) * 1992-01-21 1992-03-11 Glaxo Group Ltd Chemical compounds
JPH05339240A (ja) * 1992-06-04 1993-12-21 Yamanouchi Pharmaceut Co Ltd テトラヒドロイソキノリンアミド誘導体
DE4227203C2 (de) * 1992-08-17 1994-03-24 Kao Corp Gmbh Mittel und Verfahren zur Haarbehandlung
JPH06199892A (ja) * 1992-09-14 1994-07-19 Takeda Chem Ind Ltd Ｔａｎ−１６６６関連化合物
GB9222486D0 (en) * 1992-10-26 1992-12-09 Merck Sharp & Dohme Therapeutic agents
US5716625A (en) * 1994-12-21 1998-02-10 Cosmederm Technologies Formulations and methods for reducing skin irritation

Also Published As

Publication number Publication date
FR2728265B1 (de) 1997-02-07
MX9505181A (es) 1997-02-28
DE69522188D1 (de) 2001-09-20
AR000509A1 (es) 1997-07-10
HU9503624D0 (en) 1996-02-28
JPH08208506A (ja) 1996-08-13
ES2160680T3 (es) 2001-11-16
US5679360A (en) 1997-10-21
FR2728265A1 (fr) 1996-06-21
CA2165520C (fr) 2002-12-17
CA2165520A1 (fr) 1996-06-20
EP0717997B1 (de) 2001-08-16
PL311916A1 (en) 1996-06-24
US20020068072A1 (en) 2002-06-06
BR9505382A (pt) 1997-10-28
EP0717997A1 (de) 1996-06-26
RU2146519C1 (ru) 2000-03-20
ATE204177T1 (de) 2001-09-15
HUT74746A (en) 1997-02-28
HU218921B (hu) 2000-12-28

Similar Documents

Publication Publication Date Title
ATE204177T1 (de) Verwendung von substanz p antagonist im pharmazeutischer zusammensetzung
ATA900296A (de) Verwendung von n-glyoxylprolylesterverbindungen in arzneimitteln
FI955051A0 (fi) Heterosyklisiä yhdisteitä ja niiden valmistus ja käyttö
BR1100824A (pt) Composto e composição farmacêutica
EE04399B1 (et) Spiroasabitsüklilised heterotsüklilised ühendid, nende valmistamise protsess, neid sisaldavad ravimkoostised ja nende kasutamine ravis
DE69609353T2 (de) In der therapie verwendbare chinolin- und chinazolinverbindungen
DE59912910D1 (de) Verwendung von Nanodispersionen in pharmazeutischen Endformulierungen
ATE238342T1 (de) Neue thrombin-inhibitoren, deren herstellung und verwendung
BR9505368A (pt) Composição cosmética ou dermatogógico água-em-óleo
DE69513307T2 (de) Zusammensetzung und verwendung
ATE253582T1 (de) Prodrogs und analoga von camptothecin und deren verwendung als arzneimittel
EE04681B1 (et) 3,6-poolketaalid 9a-asaliidide klassist, nende valmistamismeetod ja farmatseutiline kompositsioon
DE69510228D1 (de) Piperidinessigsäurederivate und ihre verwendung als fibrinogenantagonistmittel
BR9509688A (pt) Composto e composição farmacêutica
BR9612413A (pt) Composto uso do mesmo e composição farmacêutica
DE69524590D1 (de) Zusammensetzung von 5htida und 5htid antagonisten
PT986537E (pt) Novos compostos heteroetinilenos e composicoes farmaceuticas e cosmeticas contendo-os
FI971317A0 (fi) Uusia heterosyklisiä, substituoituja imidatsolokinoksalinoneja, niiden valmistus ja käyttö
DE59502325D1 (de) Arzneimittelszusammensetzung aus S-Milchsäure und dessen Verwendung
DE69523404D1 (de) Verwendung von dihydrobenzofuranonen als parfüminhaltstoffe
DE10199041I1 (de) Niedrig dosierte Zusammensetzung enthaltend Benazepril und Hydrochlorthiazid
BR9505130A (pt) Composto e composiçao farmacêutica
IT1272935B (it) Composizione farmaceutica contenente n-acetil-cisteina
BR1101071A (pt) Composição e emulsão farmacêuticas
DE69132927D1 (de) Verwendung von Dihydropyridinen in kardiotonischen pharmazeutischen Zusammensetzungen

Legal Events

Date Code Title Description
8363 Opposition against the patent
8331 Complete revocation